Performance. Defined.

InVitria Blog | Cell Culture and Biotech Manufacturing Insights

Jeanne McAdara Ph.D.

Jeanne McAdara Ph.D.
Dr. McAdara is part of InVitria's medical and scientific communications team. She has been involved in scientific communications for 19 years and is the Principal of Biolexica Health Science Communications. Dr. McAdara earned her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute and was a postdoctoral fellow in the Jonsson Comprehensive Cancer Center, where she studied the biochemical and cellular mechanisms underlying leukemia.
Find me on:

Recent Posts

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

Posted By Jeanne McAdara Ph.D. on 6/24/20 9:33 AM

HEK293t cells are an indispensable tool for the production of the viral vectors at the heart of cell and gene therapy technology. To introduce a way to improve performance, consistency, and safety of your HEK293-based production InVitria’s team released a new video that talks about our serum-free chemically defined media product, OptiPEAK HEK293t Complete Media.

Read More

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Posted By Jeanne McAdara Ph.D. on 6/12/20 8:00 AM

SARS-CoV-2 continues to circulate the globe, causing widespread illness, loss of life , and far-reaching societal and economic disruption. Public health measures like stay-at-home and safer-at-home have been successful in checking the virus’s geometric growth curve, and treatments are in development. However, epidemiologists generally agree that achieving “herd immunity” through a safe and effective vaccine is indispensable to overcoming this challenge to humanity’s social, mental, and economic health and wellbeing.

Read More

Cellastim S Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Posted By Jeanne McAdara Ph.D. on 5/9/19 11:00 AM

The number and breadth of applications for induced human embryonic and pluripotent stem cells (hi-ESCs and hi-PSCs) in both research and clinical settings continue to co-evolve with our understanding of how to harness them as biological tools.

Read More

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Posted By Jeanne McAdara Ph.D. on 4/16/19 2:00 PM

Enhanced liquid-phase stability of live-attenuated Flavivirus vaccines using recombinant albumin

The single-stranded RNA viruses belonging to the genus Flavivirus (family, Flaviviridae) are significant to global public health due to the high rates of morbidity and mortality they cause.1 For example, Yellow Fever sickens approximately 200,000 people and kills 30,000 annually.2 Other viruses belonging to this genus include the mosquito-borne diseases Dengue Fever, Japanese encephalitis, West Nile virus, and Zika virus, and the tick-borne diseases Tick-borne Encephalitis, Kyasanur Forest Disease, Alkhurma disease, and Omsk hemorrhagic fever.

Read More

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

Posted By Jeanne McAdara Ph.D. on 2/19/19 10:00 AM

On Tuesday, the vaccine company FluGen announced promising preliminary results from a placebo-controlled, Phase 2 clinical trial of their investigational intranasal influenza vaccine, M2SR, in 99 healthy adults challenged with the A/Belgium/4217/2015, H3N2 strain.

Read More